Teva Pharmaceutical Industries (TEVA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Teva Pharmaceutical Industries

NYSE•Healthcare•Drug Manufacturers - Specialty & Generic

$36.76+0.40(0.01%)Pre-market

Market Cap

$45.66B

P/E

64.4x

P/S

2.6x

P/B

5.9x

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

How this company scores

GoodMetricSide Score: 61/100

Strongest: Growth (17/25); weakest: Profitability (14/25).

Profitability14/25

Growth17/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality15/25

Strengths

Rising free cash flowRising earningsInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 64.4x5y range 14.3x – 64.4x

Currently above its 6-quarter median.

P/S · 2.6x5y range 0.5x – 2.6x

Currently above its 20-quarter median.

P/B · 5.9x5y range 0.8x – 5.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.3x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $45.66B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $17.32B
Q. Revenue: $4.14B
TTM EBITDA: $2.59B
TTM Op. Income: $1.60B
Q. Op. Income: $-231.00M
TTM Net Income: $709.00M
Q. Net Income: $-575.00M
EPS: $-0.49
Shares Out.: $1.17B

$17.32B in TTM revenue grew 4.1% YoY, reaching $4.14B last quarter. TTM EBITDA of $2.59B and TTM operating income of $1.60B show growth is flowing through to the bottom line. TTM net income of $709.00M means revenue is converting into profit. Over the past year, TTM revenue is up 4% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 52.0%
EBITDA Margin: 0.2%
Op. Margin: -5.6%
Net Margin: -13.9%

Op. margin of -5.6% is down 16.5% YoY — costs are rising relative to revenue. Net margin at -13.9% and gross margin of 52.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 151% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 64.4x
P/S Ratio: 2.6x
P/B Ratio: 5.9x

At 64.4x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.6x and P/B of 5.9x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $39.86B
Cash: $3.65B
Long-Term Debt: N/A
Book Value: $7.75B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $411.00M
TTM Free Cash Flow: $1.35B
FCF Margin: 7.8%
FCF / Net Income: 1.9

TTM FCF of $1.35B on $411.00M in operating cash flow. The FCF / Net Income ratio of 1.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.